Larimar Therapeutics Submits First Module of BLA for Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) submitted the first module of its Biologics License Application (BLA) to the FDA on June 29, 2026, seeking accelerated approval for its therapy Nomlabofusp. The company plans to submit remaining modules in H2 2026.

By Muhammad Ali Khalid Wed, July 15, 2026 at 6:43 PM GMT+3 2 min read · Yahoo Finance · July 15, 2026, 15:43 UTC

Larimar Therapeutics Submits First Module of BLA for Nomlabofusp Therapy

Tickers: $LRMR

Topics: biotech clinical trials drug approval

Read the full article at Yahoo Finance

More World news

Oman Investment Authority Signs Multi-Billion Dollar Investment Package with Chinese Partners PR Newswire · November 12, 2026, 15:52 UTC
Nvidia Shares Drop 35% Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:49 UTC
Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro (CLPT) PR Newswire · November 12, 2026, 15:50 UTC
Nvidia CEO Jensen Huang Resigns Amid Board Investigation The Verge · November 12, 2026, 15:48 UTC
GFL Environmental Shares Decline Following Preferred Share Conversion and Block Trade Seeking Alpha · November 12, 2026, 15:48 UTC
Medical Facilities Corp. Announces CAD 0.09 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 15:45 UTC
Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC